New MRI technique may tell doctors if cancer is gone before surgery
NCT ID NCT06719414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special type of MRI, called amide proton transfer-weighted imaging, can accurately predict if rectal cancer has completely disappeared after chemotherapy and radiation. Researchers will compare the MRI results with the actual tissue removed during surgery. The goal is to help doctors know if surgery is still needed, potentially avoiding unnecessary operations. About 320 adults with locally advanced rectal cancer who have completed neoadjuvant therapy will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 320 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with locally advanced rectal cancer treated with neoadjuvant therapy
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma * Received neoadjuvant therapy before surgery * Complete radical resection of rectal cancer and postoperative pathological examination * Informed consent and signed the informed consent form Exclusion Criteria: * Poor image quality, such as severe artifacts * Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment * The interval between preoperative MRI and surgery was more than 2 weeks * Prior treatment for rectal cancer * History of other malignant tumors * Patients who cannot undergo MRI examination due to contraindications or relative contraindications * Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally advanced rectal adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
-
Xinyi People's Hospital
NOT_YET_RECRUITINGMaoming, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can immunotherapy plus chemo melt colorectal tumors before surgery?
- Can drug cocktail spare rectal cancer patients from surgery?
- Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
- Can digital surveys capture the full toll of rectal cancer treatment?
- Can a targeted drug conjugate outsmart advanced colorectal cancer?